Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03748173 · ClinicalTrials.gov registry record · Phase 1
Infasurf®(Calfactant) Aerosol for Infants With Bronchiolitis-AERO-04
A Phase 1 study, sponsored by ONY.
- Terminated
- Registry status
- Phase 1
- Development phase
- 13
- Enrollment target
NCT03748173 is a Phase 1 study that was terminated before completion, run by ONY. The registered enrollment target is 13 participants.
The verdict
NCT03748173, a Phase 1 study, was terminated before completion, sponsored by ONY.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 13 participants
- Enrollment target
Study Summary
Delivery of aerosolized Infasurf to bronchiolitis patients with who are not on assisted ventilation can provide sufficient delivery of Infasurf to small airways to improve ventilation and thereby shorten the duration of the respiratory illness.
Interventions
- COMBINATION_PRODUCT Aerosolized Infasurf
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13 participants |
| Start Date | 2019-01-12 |
| Est. Completion | 2020-10-21 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03748173
The ClinicalTrials.gov registry entry for NCT03748173 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 13 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is ONY, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Aerosolized Infasurf is the first listed.
NCT03748173 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03748173 about?
NCT03748173 is a clinical study titled "Infasurf®(Calfactant) Aerosol for Infants With Bronchiolitis-AERO-04". Delivery of aerosolized Infasurf to bronchiolitis patients with who are not on assisted ventilation can provide sufficient delivery of Infasurf to small airways to improve ventilation and thereby shorten the duration of the respiratory illness.
What is the current status of trial NCT03748173?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 13 participants. The study started on 2019-01-12. Estimated completion is 2020-10-21.
What interventions are being tested in trial NCT03748173?
The interventions under investigation include: Aerosolized Infasurf (COMBINATION_PRODUCT).
Who is sponsoring clinical trial NCT03748173?
This trial is sponsored by ONY, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.